| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Division of Nuclear Medicine (Drs. Kuhl, Koeppe, Minoshima, Snyder, Ficaro, Frey, and Kilbourn) and the Department of Neurology (Drs. Foster and Frey), University of Michigan, Ann Arbor, MI.
Address correspondence and reprint requests to Dr. D.E. Kuhl, University of Michigan Hospitals, Division of Nuclear Medicine, 1500 East Medical Center Drive, Ann Arbor, MI 48109-0028; e-mail: dkuhl{at}umich.edu
OBJECTIVE: To validate an in vivo method for mapping acetylcholinesterase (AChE) activity in human brain, preparatory to monitoring inhibitor therapy in AD.
BACKGROUND: AChE activity is decreased in postmortem AD brain. Lacking a reliable in vivo measure, little is known about central activity in early AD, when the disease is commonly targeted by AChE inhibitor drug therapy.
METHODS: Intravenous N-[11C]methylpiperidin-4-yl propionate ([11C]PMP) served as an in vivo AChE substrate. AChE activity was defined using cerebral PET for tracer kinetic estimates of the local rate of [11C]PMP hydrolysis in 26 normal controls and 14 patients with AD. Eleven AD patients also had concomitant in vivo cerebral measures of vesicular acetylcholine transporter (cholinergic terminal) density and glucose metabolism.
RESULTS: Cerebral AChE activity measures 1) were independent of changes in tracer delivery to cerebral cortex; 2) agreed with reported postmortem data concerning normal relative cerebral distributions, absence of large age-effect in normal aging, and deficits in AD; 3) correlated in AD cerebral cortex with concomitant in vivo measures of cholinergic terminal deficits, but not with metabolic deficits; and 4) agreed quantitatively with predicted level of cerebral AChE inhibition induced by physostimine.
CONCLUSIONS: This in vivo PET method provided valid measures of central AChE activity in normal subjects and AD patients. Applied in early AD, it should facilitate inhibitor treatment by confirming central inhibition, optimizing drug dosage, identifying likely responders, and testing surrogate markers of therapeutic response.
This article has been cited by other articles:
|
|
 |
|
  H. Shimada, S. Hirano, H. Shinotoh, A. Aotsuka, K. Sato, N. Tanaka, T. Ota, M. Asahina, K. Fukushi, S. Kuwabara, et al. Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET Neurology, July 28, 2009; 73(4): 273 - 278. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Dai, O. L. Lopez, O. T. Carmichael, J. T. Becker, L. H. Kuller, and H. M. Gach Mild Cognitive Impairment and Alzheimer Disease: Patterns of Altered Cerebral Blood Flow at MR Imaging Radiology, March 1, 2009; 250(3): 856 - 866. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K HERHOLZ, S F CARTER, and M JONES Positron emission tomography imaging in dementia Br. J. Radiol., December 1, 2007; 80(Special_Issue_2): S160 - S167. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Genazzani, N. Pluchino, S. Luisi, and M. Luisi Estrogen, cognition and female ageing Hum. Reprod. Update, March 1, 2007; 13(2): 175 - 187. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Hirano, H. Shinotoh, T. Kobayashi, Y. Tsuboi, Z. K. Wszolek, A. Aotsuka, N. Tanaka, T. Ota, K. Fukushi, S. Tanada, et al. Brain acetylcholinesterase activity in FTDP-17 studied by PET Neurology, April 25, 2006; 66(8): 1276 - 1277. [Full Text] [PDF]
|
|
|
|
 |
|
 W.-D. Heiss and K. Herholz Brain Receptor Imaging J. Nucl. Med., February 1, 2006; 47(2): 302 - 312. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N I Bohnen, D I Kaufer, R Hendrickson, L S Ivanco, B J Lopresti, R A Koeppe, C C Meltzer, G Constantine, J G Davis, C A Mathis, et al. Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer's disease J. Neurol. Neurosurg. Psychiatry, March 1, 2005; 76(3): 315 - 319. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Saykin, H. A. Wishart, L. A. Rabin, L. A. Flashman, T. L. McHugh, A. C. Mamourian, and R. B. Santulli Cholinergic enhancement of frontal lobe activity in mild cognitive impairment Brain, July 1, 2004; 127(7): 1574 - 1583. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Blandina, M. Efoudebe, G. Cenni, P. Mannaioni, and M. B. Passani Acetylcholine, Histamine, and Cognition: Two Sides of the Same Coin Learn. Mem., January 1, 2004; 11(1): 1 - 8. [Full Text] [PDF]
|
|
|
|
 |
|
 N. I. Bohnen, D. I. Kaufer, L. S. Ivanco, B. Lopresti, R. A. Koeppe, J. G. Davis, C. A. Mathis, R. Y. Moore, and S. T. DeKosky Cortical Cholinergic Function Is More Severely Affected in Parkinsonian Dementia Than in Alzheimer Disease: An In Vivo Positron Emission Tomographic Study Arch Neurol, December 1, 2003; 60(12): 1745 - 1748. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. V. Terry Jr and J. J. Buccafusco The Cholinergic Hypothesis of Age and Alzheimer's Disease-Related Cognitive Deficits: Recent Challenges and Their Implications for Novel Drug Development J. Pharmacol. Exp. Ther., September 1, 2003; 306(3): 821 - 827. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Bilgi, S. Tokgoz, A. Aydin, T. Celik, and I. T. Uzbay THE EFFECTS OF CHRONIC ETHANOL CONSUMPTION AND ETHANOL WITHDRAWAL ON SERUM CHOLINESTERASE ACTIVITY IN RATS Alcohol Alcohol., July 1, 2003; 38(4): 316 - 320. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J O Rinne, V Kaasinen, T Jarvenpaa, K Nagren, A Roivainen, M Yu, V Oikonen, and T Kurki Brain acetylcholinesterase activity in mild cognitive impairment and early Alzheimer's disease J. Neurol. Neurosurg. Psychiatry, January 1, 2003; 74(1): 113 - 115. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. R. Smith, S. Minoshima, D. E. Kuhl, and J.-K. Zubieta Effects of Long-Term Hormone Therapy on Cholinergic Synaptic Concentrations in Healthy Postmenopausal Women J. Clin. Endocrinol. Metab., February 1, 2001; 86(2): 679 - 684. [Abstract] [Full Text]
|
|
|
|
|
|
H. Shinotoh, A. Aotsuka, K. Fukushi, S. Nagatsuka, N. Tanaka, T. Ota, S. Tanada, and T. Irie Effect of donepezil on brain acetylcholinesterase activity in patients with AD measured by PET Neurology, January 13, 2001; 56(3): 408 - 410. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Pain, H. Jeltsch, O. Lehmann, C. Lazarus, F. Z. Laalou, and J. C. Cassel Central cholinergic depletion induced by 192 IgG-Saporin alleviates the sedative effects of propofol in rats Br. J. Anaesth., December 1, 2000; 85(6): 869 - 873. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. R. Reed and W. J. Jagust Opening a window on cerebral cholinergic function Neurology, March 1, 1999; 52(4): 680 - 680. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
